EBS - U.S. red tape preventing millions of AstraZeneca vaccine doses from being shipped

Tens of millions of doses of AstraZeneca's (AZN) COVID-19 vaccine are sitting in U.S. facilities as the company has not yet finished its U.S. clinical trial and has yet to apply for Emergency Use Authorization from the FDA, The New York Times reports.Given that many countries have authorized the vaccine and AstraZeneca has been saddled with manufacturing issues, critics say the U.S. government should allow the doses to be sent to other countries where they are needed.AstraZeneca has asked the Biden administration to relinquish some of those doses so it can be sent to the European Union, but that request has been rebuffed so far, according to the Times article.Around 30M doses are sitting in an AstraZeneca facility in Ohio.Emergent BioSolutions (EBS), which AstraZeneca has contracted with to help with manufacturing, is sitting on tens of millions of doses awaiting fill-finish, the last stage of the production process.AstraZeneca shares are down

For further details see:

U.S. red tape preventing millions of AstraZeneca vaccine doses from being shipped